Search

Displaying results 7491 - 7500 of 8696 in total
  1. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.

  2. Drug

    Bekanamycin

    go.drugbank.com/drugs/DB13673
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    INKP-102

    go.drugbank.com/drugs/DB05326
    Experimental

    INKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.

  4. Drug

    G305

    go.drugbank.com/drugs/DB17292
    Investigational

    G305 is an active component of CMB305 along with [LV305].[L47346]

  5. Drug

    UM-171

    go.drugbank.com/drugs/DB19449
    Investigational

    UM-171 is a pyrimidoindole derivative that is an agonist of ex vivo hematopoietic stem cell expansion and thus supports the expansion of hematopoietic stem cells.[A264868, A264873]

  6. Drug

    Rebaudioside A

    go.drugbank.com/drugs/DB15136
    Investigational

    Rebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).

  7. Drug

    Myrcludex B

    go.drugbank.com/drugs/DB14853
    Investigational

    Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination

  8. Drug

    Thienylfentanyl

    go.drugbank.com/drugs/DB09180
    ExperimentalIllicit

    Thienylfentanyl has a similar synthesis pathway to fentanyl except 2-(2-bromoethyl)thiophene is substituted for phenethyl bromide.

  9. Drug

    Maduramicin

    go.drugbank.com/drugs/DB11525
    ExperimentalVet approved

    Maduramicin is an antiprotozoal agent used in veterinary medicine as prophylaxis against coccidiosis.

  10. Drug

    OTL-203

    go.drugbank.com/drugs/DB18643
    Investigational

    OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.